

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 4, 2018**

**ARCH THERAPEUTICS, INC.**  
(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**000-54986**  
(Commission  
File Number)

**46-0524102**  
(I.R.S. Employer  
Identification No.)

**235 Walnut Street, Suite 6**  
**Framingham, Massachusetts**  
(Address of principal executive offices)

Registrant's telephone number, including area code: **(617) 431-2313**

**01702**  
(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 7.01 Regulation FD Disclosure.**

On December 4, 2018, Arch Therapeutics, Inc. (the “**Company**”) issued a press release to announce the positive outcome of a ruling from the Japanese Intellectual Property High Court. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 8.01 Other Events.**

The disclosure under Item 7.01 (Regulation FD Disclosure) is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) The following exhibits are being filed herewith:

<b>Exhibit</b>	<b>Description</b>
<u>99.1</u>	<u><a href="#">Press Release issued by Arch Therapeutics, Inc. on December 4, 2018</a></u>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ARCH THERAPEUTICS, INC.**

Dated: December 4, 2018

By: /s/ Terrence W. Norchi, M.D.  
Name: Terrence W. Norchi, M.D.  
Title: President, Chief Executive Officer

---

## **Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court**

**Massachusetts Institute of Technology and Versitech Limited patent, licensed exclusively by Arch, is maintained without amendment as prior lower court decision is affirmed.**

FRAMINGHAM, Mass., December 4, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is pleased to announce that the Japanese Intellectual Property High Court has favorably ruled to affirm the prior trial decision and maintain without any amendments Japanese patent number 5204646 ('646). This patent is part of the intellectual property estate that Arch has licensed globally and exclusively from the Massachusetts Institute of Technology and Versitech Limited ("MIT").

The '646 patent was challenged in a Japanese court by an opponent. Previously, a Japanese Court issued a decision in our favor to maintain the patent in its entirety. The opponent appealed the decision. On October 30, 2018, the Japanese Intellectual Property High Court affirmed the lower court decision to maintain the patent in its entirety. The opponent has one remaining right to appeal this decision.

Chief Executive Officer, Terrence W. Norchi, MD, said, "We value both our licensed and internally developed intellectual property. We appreciate the court's reaffirmation of the patent rights and reserve the right to protect and defend our technology."

As previously announced, Arch filed a 510(k) premarket notification for AC5™ Topical Gel in the United States in the third calendar quarter of 2018. The submission is under review. Further, Arch filed a CE mark for AC5™ Topical Hemostat during the fourth calendar quarter of 2018.

Norchi added, "These next weeks, months, and quarters are important to Arch as we continue to develop our products for commercialization in the US and Europe."

### **About Arch Therapeutics, Inc.**

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5™ Topical Gel<sup>1</sup>, AC5™ Topical Hemostat<sup>1</sup> and AC5™ Surgical Hemostat<sup>1</sup>.

---

## **Notice Regarding Forward-Looking Statements**

This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at [www.sec.gov](http://www.sec.gov).

Source: Arch Therapeutics, Inc.

## **Contact**

ARTH Investor Relations  
Toll Free: +1-855-340-ARTH (2784) (US and Canada)  
Email: [investors@archtherapeutics.com](mailto:investors@archtherapeutics.com)  
Website: [www.archtherapeutics.com](http://www.archtherapeutics.com)

or

Richard Davis  
Chief Financial Officer  
Arch Therapeutics, Inc.  
Phone: 617-431-2308  
Email: [rdavis@archtherapeutics.com](mailto:rdavis@archtherapeutics.com)  
Website: [www.archtherapeutics.com](http://www.archtherapeutics.com)

1. AC5 is currently an investigational device and is limited by federal law to investigational use.
-